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Executive Summary
Nigeria is committed to achieving a modern contraceptive prevalence rate of 27 percent by 2020; yet current
estimates show only 11 percent of women age 15-49 years old use modern contraceptive methods. Among
both public and private family planning (FP) service providers, Patent and Proprietary Medicine Vendors
(PPMV) are the most popular source for voluntary contraceptive services. According to Nigeria’s 2013 National
Demographic Health Survey, 38 percent of all contraceptive users and 13 percent of injectable users received
their method from a PPMV.
The Evidence Project, led by the Population Council with support from the U.S. Agency for International
Development, collaborated with the Federal Ministry of Health (FMoH), state ministries of health, and professional associations to conduct an implementation science study in Bauchi, Cross River, Ebonyi, Kaduna,
Nasarawa and Oyo States representing each of Nigeria’s six geo-political zones. The study objectives were to:
• Assess the feasibility of PPMVs in the provision, specifically the administration, of voluntary injectable
contraceptives1; and
• Explore injectable contraceptive users’ experiences and quality of care received when accessing contraceptive services from PPMVs.
PPMVs received a 1-week training on FP counseling, sale, referral and administration of all progestin-only
injectable contraceptives. Trainings in Nasarawa and Oyo were held in November 2015, and in Bauchi, Cross
River, Ebonyi and Kaduna in May and June of 2017. Learnings from Nasarawa and Oyo were applied to
the implementation process in Bauchi, Cross River, Ebonyi and Kaduna, including an observation checklist
that was added to the monitoring visits one and six months after the training. Monitoring teams comprised
of national, state and local-level ministry officials, National Association of Patent and Proprietary Medicine
Dealers (NAPPMED) and Pharmacy Council of Nigeria (PCN) representatives visited PPMVs two-to-three
times over nine months.
Trained data collectors conducted face-to-face interviews with PPMVs before, after, and nine months following
the training. Injectable contraceptive clients were interviewed within five days after receiving an injection from
a trained PPMV and were followed over nine months by phone. Written informed consent was obtained from
all respondents participating in the study. The research protocol received ethical approval from the Population
Council’s Institutional Review Board, National Health Research Ethic Committee, the Ethical Committee at
University of Ibadan and ethics committees based at state ministries of health in Bauchi, Cross River, Ebonyi
and Kaduna.
Almost all PPMVs were providing some form of injectable contraceptive services (counseling, sale, referral or
administration) and 49 percent had administered an injectable in their shop before the training. Forty percent
of clients had visited a study-enrolled PPMV for injectable services before the trainings. Key study findings are
summarized below:
PPMVs can administer injectable contraceptives safely
• PPMVs demonstrated competency in nine key steps for safe administration of intramuscular depot
1 DMPA-IM (Depo-Provera), NET-EN (Noristerat) and DMPA-SC (Sayana Press)
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medroxyprogesterone acetate (DMPA-IM) and nine key steps for safe administration of subcutaneous
DMPA (DMPA-SC) using models immediately and six months after the training in front of a Master
Trainer in Bauchi, Cross River, Ebonyi and Kaduna.
• Nearly all PPMVs (98%) were observed having a sharps disposal box in use in their shop by the monitoring teams in Bauchi, Cross River, Ebonyi and Kaduna.
There was no difference in knowledge and skills between PPMVs with and without previous health
facility experience
• PPMVs without prior health facility experience had similar or higher levels of knowledge to those with
health facility experience on:
–– 44 of the 50 injectable contraceptive characteristics at the post-training survey
–– 46 of the 50 injectable contraceptive characteristics at the 9-month follow-up survey
• PPMVs with no health facility experience demonstrated similar levels of competency in almost all
the steps required for safe administration of DMPA-IM and DMPA-SC to those with health facility
experience.
PPMVs’ knowledge of injectable contraceptive characteristics was higher after the training and
PPMVs retained this knowledge nine months later
• PPMVs had significantly higher knowledge on 47 of 50 injectable contraceptive indicators2 post-training.
• PPMV retained or improved knowledge for 42 of the 50 indicators at the 9-month follow-up survey.
Knowledge specifically increased for 13 of those 42 indicators.
• Despite overall knowledge gains across most indicators, knowledge on some indicators like side effects
and exclusionary health conditions remained low at the 9-month follow-up survey. Non-prompted
questions were used to assess PPMVs knowledge. These questions may not accurately reflect PPMVs
knowledge as clients reported receiving key information from PPMVs, specifically side effects, and
86% of PPMVs reported using either the MEC wheel, BCS cards and or DMPA screen checklist, when
counseling their clients.
Clients reported receiving quality FP counseling and were satisfied with injectable services
received from PPMVs
• Over 80 percent of clients reported receiving information on 9 quality of care indicators3 at their first
injection visit from a trained PPMV. At their second and third injection visits, most clients continued to
report quality counseling.
• Over 97 percent of clients reported that they would return to the PPMV for their next injection and 100
percent would recommend that PPMV to a friend for injectable contraceptive services.

2 The 50 indicators are described in the Results section starting on page 20 and include: side effects (7), exclusionary health conditions (11),
when a woman can start the injectable (6), instructions for clients after the injection (6), method-specific characteristics (9), how to handle
needles safely (5), how to avoid infection from needlestick injury (3), and what to do if there is a needlestick injury (3)
3 The 9 quality of care indicators include: (1) being asked the reason for your visit; (2) told about other FP methods; (3) asked about previous
use of the injectable (4) asked about reasons for choosing the injectable (5) told when to return for the next injection (6) told what to do if
you experiences a problem with the injectable; (7) told about potential side effects (8) told about potential actions to resolve problems with
the side effect; and (9) reported feeling comfortable asking questions.
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Clients who discontinued the injectable contraceptive did so for reasons unrelated to PPMV
service quality
• Of the 22 percent of clients (66/294) in Bauchi, Cross River, Ebonyi and Kaduna who reported discontinuing the injectable contraceptive method or stopping injectable services from PPMVs, the top three reasons were: didn’t have time to go back (21%); wanted to become pregnant (20%), and side effects (18%).
Clients reported a variety of reasons for seeking injectable contraceptive services from PPMVs. Many do so
because it is more convenient. Policy change that would allow PPMVs to offer injectable administration could
improve access to FP counseling and injectable contraceptives for more women throughout Nigeria. If policy
were to be changed, the following considerations could assist in scale-up:
• The curriculum used in this study was based on existing, validated materials. Most PPMVs strongly
agreed that the curriculum used in this study improved their knowledge and skills to provide FP counseling and voluntary injectable contraceptive services. Using existing materials can help save time when
training PPMVs in injectable contraceptive service provision.
• Job aids that are designed to help providers adhere to counseling and screening guidelines are acceptable
to PPMVs. Most PPMVs used the job aids that were provided in the study; job aids can help alleviate
the burden of memorizing long lists of information.
• Better linkages between the PPMVs and the public sector are needed to ensure effective referrals for any
contraceptive method and proper disposal of sharps.
• PPMVs require monitoring support by the state and local governments. Additional support would be
needed to ensure PPMVs do not experience harassment from law officials. This potential for harassment
can prohibit PPMVs from keeping up-to-date records of FP counseling, and sale and administration of
injectable contraceptives.
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Introduction
With a population of approximately 214 million people, Nigeria is Africa’s most populous nation (Population
Reference Bureau, 2018). Modern contraceptive methods remain underutilized in Nigeria (only 11% of married
women of reproductive age use modern contraceptives) [MICS, 2017] despite efforts to expand access to FP
over the past two decades. Approximately 40 percent of modern contraceptive users use an injectable contraceptive, 21 percent use oral contraceptives, 13 percent use an implant, 10 percent use male condoms and 16
percent use various other methods (MICS, 2017). Among both public and private sources, PPMVs are the most
popular source for modern contraceptives (NPC and ICF, 2014) for many reasons including (a) widespread
availability throughout Nigeria, (b) consistent drug stocks, (c) extended operational hours including weekends,
(d) personable interactions, and (e) no separate fees for consultations (Brugha 2002; Adetunji 1991). Nigerian
pharmacy laws prohibit PPMVs from selling and administering injectable contraceptives due to a lack of formal
training in injectable contraceptive services (NPC, 2008 & 2003). Even with this restriction, 13 percent of
injectable contraceptive users received an injectable contraceptive from a PPMV (NPC and ICF, 2014).
The FMoH recognizes the important role that PPMVs can play in the delivery of modern contraceptive services and recommends that PPMVs should motivate, counsel, and refer clients for contraceptive services,
supply non-prescription contraceptives, and resupply oral contraceptive pills (FMoH, 2009). Although several
studies have explored the role of PPMVs in offering contraceptive services broadly (Oye-Adeniran et al, 2006;
Ajayi, 2009), few have specifically assessed the contribution of PPMVs in delivering injectable contraceptives, the implementation considerations, and their clients’ experiences receiving these services (Ajuwon et al.
2013). For these reasons, the Evidence Project, led by the Population Council and funded by the United States
Agency for International Development (USAID), collaborated with the FMoH and state ministries of health
to conduct an implementation science study to assess the feasibility and acceptability of PPMVs’ provision of
injectable contraceptive services.
This report summarizes the results of the implementation science study and identifies programmatic implications for PPMVs to safely deliver injectable contraceptive services, including the mentorship and support that
would be needed if PPMVs were legally allowed to administer injectable contraceptives. Results from this study
will contribute to task shifting4 policy in Nigeria with the potential to improve women’s access to contraceptive
services offered by PPMVs.

4 Task shifting is the shifting of specific tasks or services that have traditionally been done by specialized health workers to those with less
training (WHO, 2007)
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Objectives
The goal of this study was to improve access of voluntary family planning services for women and couples in
Nigeria. The study objectives were to:
• Assess the feasibility of PPMVs in the provision, specifically the administration of DMPA-IM (DepoProvera), NET-EN (Noristerat), and DMPA-SC (Sayana Press); and
• Explore the experiences of injectable contraceptive users and the quality of care they receive when
accessing injectable contraceptive services from PPMVs.
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Methods
Study design
The study was implemented in Bauchi, Cross River, Ebonyi, Kaduna, Nasarawa and Oyo states. PPMVs enrolled
in the study participated in a five-day training covering FP counseling and the provision of progestin-only
injectable contraceptive services (including counseling, sale, referral and administration), and were routinely
monitored after the training. USAID Washington funded implementation in Nasarawa and Oyo states. The
USAID Mission in Nigeria provided additional funding to expand the study to Bauchi, Cross River, Ebonyi,
and Kaduna so that the overall study included one state from each geo-political zone. Ministry officials, Master
Trainers, non-governmental organizations (NGOs), professional associations, and the Population Council
modified the intervention and the study design for Bauchi, Cross River, Ebonyi and Kaduna by reviewing
results and implementation experiences from Oyo and Nasarawa. The modifications included (a) adjusting the
PPMV data collection and monitoring time points, (b) adding questions to the PPMV and client survey tools,
(c) updating the training curriculum, and (d) providing PPMVs with job aids.
The overall study design remained the same despite these modifications. In all six states, the Evidence Project
collected data from PPMVs and their injectable contraceptive clients over a 9-month period.

Study population and recruitment
The study took place in six of the 36 states in Nigeria: Bauchi, Cross River, Ebonyi, Kaduna, Nasarawa and
Oyo. The states were selected in collaboration with the FMoH and the USAID Mission in Nigeria to represent
each of the six geopolitical zones of Nigeria. In each state, four Local Government Areas (LGAs), (two urban
and two rural) were randomly selected by simple balloting for a total of twenty-four. The categorization of
rural or urban LGAs was obtained from state government websites. The number and selection of LGAs were
determined in collaboration with the respective states’ ministries of health.
Patent and proprietary medicine vendors
PPMVs are frontline service providers who operate in Nigeria’s informal health sector. In Nigeria, a PPMV is
defined by the Pharmacy Law as someone who is licensed by the State Ministry of Health to sell pre-packaged,
over the counter medications (FMoH, 1946). The Pharmacy Law requires that applicants be at least 21 years
old and submit the names of two references to obtain a license. By custom, PPMVs are expected to have completed a minimum of primary school education (Liu, 2014). Most PPMVs learned to sell and dispense medicine
through apprenticeships with licensed PPMVs.
In Nasarawa and Oyo, announcements were made during NAPPMED meetings in each of the study LGAs.
NAPPMED is the main professional association of PPMVs in Nigeria. The announcement included the study’s
goal and methodology, and the training PPMVs would receive if enrolled. The local NAPPMED chapter nominated PPMV members using three criteria:
1. Interested and willing to participate
2. Able to read and write in English, and speak English and either Yoruba or Hausa
3. Committed to attend all training sessions
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NAPPMED sent a shortlist of candidates to the research team. PPMVs were randomly selected from that list
to participate in the study. Selected PPMVs were sent formal invitations with information on the dates and
location for the training.
In Bauchi, Cross River, Ebonyi and Kaduna, PPMVs were primarily recruited in collaboration with PCN, which
is the regulatory body for PPMVs in Nigeria. PCN was more actively engaged in the additional four states due
to its key role in overseeing PPMV services. Each PCN state officer nominated PPMVs based on the following
criteria:
• Licensed with PCN
• Interested and willing to participate
• Able to read and write in English
• Committed to attend all training sessions
NAPPMED assisted with PPMV recruitment in LGAs where PPMV licensure with PCN was low. As in
Nasarawa and Oyo, PPMVs were randomly selected from the shortlist of candidates identified by PCN. Selected
candidates were contacted and invited to trainings at the state level. PPMVs were retained in the study if they
demonstrated competence in administering DMPA-IM and DMPA-SC injections on dummy models. A Master
Trainer used an observation checklist to evaluate PPMV skills.
Injectable contraceptive clients
For a 3-month period after the training, participating PPMVs referred eligible clients to be interviewed for the
study. The referral period was extended to four months in Bauchi, Cross River, Ebonyi and Kaduna to reach
the desired sample size. Eligible clients were those who were administered a progestin-only injectable contraceptive from a trained PPMV. PPMVs informed clients about the study and requested permission to share the
client’s name and phone number with the study team for follow-up. If a client agreed to participate, a trained
data collector called the client within five days of her visit to the PPMV. At the time of the telephone interview,
the interviewer asked a set of questions to ensure that the respondent was aware of the study and then read the
informed consent statement (see section on Ethical Considerations) before proceeding with the questionnaire.
Any client who came to a PPMV outside of the 3- to 4-month referral window was not enrolled in the study.

Data collection
Data collectors training
Four data collectors and one supervisor were recruited in each state to conduct PPMV and client interviews.
Data collectors and supervisors were trained in four-day data collection training. Content included:
• an overview of the study and its goals
• a description of PPMVs and their role in the health care system
• a discussion of the importance of research ethics, including privacy and confidentiality
• the PPMVs’ role in ensuring confidentiality, privacy, and anonymity
• informed consent and the consent forms
• thorough review of interview questions and their purpose
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• the data collection timeline
• data management
The training combined traditional lecture with adult learning methodologies including role play and mock interviews with clients and PPMVs. Mock interviews were conducted with non-participating PPMVs identified by
the local NAPPMED chapter, and volunteers acted as mock clients. The supervisors received additional information on (a) their role as a supervisor, (b) the data management process, (c) how to identify data collection
issues, and (d) to how to seek guidance from the research team to resolve issues.
Data collection
Nasarawa and Oyo
Data collection for the PPMVs began in November 2015. Data collected from PPMVs included (a) a pre-test
survey and (b) 1-, 3-and 9-month follow-up surveys. The pretest survey was administered before the training
and included demographic questions and knowledge questions on injectable contraceptives (e.g. frequency and
administration location, counseling on side effects and method effectiveness, eligibility criteria, supplies, and
proper storage and disposal of drugs). Follow-up surveys were conducted in person at the PPMV’s shop one,
three and nine months after the training. The follow-up surveys were identical at each time point and included
questions on the type of injectable services provided, and the knowledge questions in the pretest survey.
Initial telephone interviews with clients were conducted between December 2015 and February 2016. The first
interview included questions on (a) client demographics, (b) previous FP and injectable use, (c) type of services
received, (d) experience and satisfaction with PPMV services, and e) satisfaction with the injectable method.
The same survey, minus the demographic questions, was administered after the respondents’ expected second
and third injection. A 2-week window after the expected injection date was used to interview clients for the follow-up surveys. Clients who were no longer using the injectable or did not receive the injectable from a trained
PPMV were not interviewed but were contacted again at the time of the next follow-up interview.
Bauchi, Cross River, Ebonyi and Kaduna
Data collection for PPMVs in Bauchi, Cross River, Ebonyi and Kaduna began in May 2017. Minor modifications were made to data collection process based on the experience in Nasarawa and Oyo. A post-test training
survey was included to compare knowledge immediately before and after the training. The follow-up surveys
were conducted only three and nine months after the training to avoid duplication with the monitoring visits
(see section on Monitoring and Supervision).
The pretest and follow-up surveys were almost identical to those used in Oyo and Nasarawa, but included additional questions related to PPMV knowledge of NET-EN and their stock of other FP methods. Data collectors
administered the post-test on the last day of the training. The post-test included the same set of questions as
the pretest survey, excluding the demographic and store practice questions.
Follow-up surveys were conducted in person at the PPMV’s shop three and nine months after the training. The
surveys included questions on the type of injectable services provided since the training and the knowledge
questions from the pre-test survey.
Initial telephone interviews with clients were conducted between May 2017 and September 2017. The first
interview and follow-up surveys were similar to those used in Nasarawa and Oyo except the follow-up surveys
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included a subset of questions for clients who stopped using the injectable or stopped receiving injectable services from PPMVs. Several questions on quality were also added to the client surveys. Based on the experience
in Nasarawa and Oyo, the interview window for follow-up surveys was extended from two to four weeks after
scheduled injection date.

Data management and analysis
Data management
Data collection supervisors checked survey data for completeness and accuracy. Completed questionnaires
were sent to the Population Council office in Abuja for review by the Program Officer. All completed surveys
were stored in locked files at the Population Council office and access to the surveys was strictly limited to the
research team. Only the Program Officer had access to respondent names, study identification numbers, and
the instruments. Completed questionnaires were entered into Statistical Package for Social Sciences (SPSS)
software and analyzed using Stata 14 software.
Data analysis
Descriptive statistics and bivariate analyses were conducted. Chi-square tests were used to determine significant
associations over time and between PPMVs with and without previous health facility experience. T-tests were
used to determine significance differences in the mean knowledge scores between the initial phase (Nasarawa
and Oyo) and the expanded phase (Bauchi, Cross River, Ebonyi and Kaduna).

Ethical considerations
Ethical review
The research protocol, including the data collection tools and informed consent forms, received ethical approval
from the Population Council’s Institutional Review Board, and the Ethical Committee, College of Medicine at
the University of Ibadan. Ethical approval was also received in each state. The FMoH approved the study. All
data collection activities involving human subjects began only after full approvals were received from relevant
ethical review boards.
Informed consent
Structured, written informed consent forms were used during in-person interviews with PPMVs and over the
phone with clients. The consent form provided respondents with (a) information on the study objectives, (b)
methodology, (c) measures to protect their privacy, confidentiality and anonymity, and (d) who to contact for
additional information or if there was a problem. Before the start of each survey, a trained data collector read
the informed consent form and explained its contents. PPMVs were given a copy to read and keep. A data
collector asked each PPMV for his/her written consent and clients for their verbal consent over the phone.
Informed consent was received by all respondents at the start of each survey.
Confidentiality
Each respondent received a unique identification (ID) number during the first interview. This unique ID code
was recorded on the questionnaires and no other personal identifying information was recorded on the questionnaires. Documents containing names of participants, including the informed consent forms, were kept physically separate from the questionnaires in a locked cabinet at the Population Council office in Abuja, Nigeria.
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Description of the Intervention
Stakeholder engagement
The Evidence Project collaborated with stakeholders throughout the life of the study including in the design,
implementation, and results interpretation phases. For example, the original protocol only included training
PPMVs to counsel, sell and refer clients for injectable services. To ensure the study’s results would provide policymakers and program implementers with the evidence needed, the Population Council in coordination with
the FMoH presented the original protocol to the National Reproductive Health Technical Working Group. At
this meeting, Technical Working Group members highlighted the need for evidence on PPMV administration
of injectable contraceptives. As a result, the protocol and intervention were expanded to include administration. Stakeholder engagement continued in the monitoring visits where national, state and local-level ministry
officials were members of the monitoring team (see section on Monitoring and Supervision).
The Evidence Project, federal, state and local ministries of health, NGOs and professional associations reviewed
the training curriculum used in Nasarawa and Oyo alongside results from these two states. The curriculum was
revised to improve outcomes for certain topics. Examples of revisions made to the curriculum and training
include:
• reduce lecture time and increase hands-on practice and small group activities
• provide a clearer definition of common side effects versus adverse events
• simplify language used in the screening checklist for injectable users
The revised curriculum was used in Bauchi, Cross River, Ebonyi and Kaduna. PPMVs in these states were
asked a series of question at the 9-month survey to understand their perceptions of the training (n=194). One
hundred percent agreed with the following two statements, 1) “the training improved my knowledge and skills
to provide injectable contraceptives” and 2) “the training improved my knowledge and skills in FP counseling”
(data not shown). When asked how easy or difficult they found the training, 72 percent said the training was
easy to very easy and 26 percent said it was moderate. Only 2 percent of PPMVs found the training to be difficult or very difficult.
Overall, knowledge outcomes were not higher in the additional four states compared to knowledge outcomes
in Oyo and Nasarawa. Knowledge of injectable contraceptive side effects, however, was higher in Bauchi, Cross
River, Ebonyi and Kaduna. The mean number of side effects named by PPMVs in Nasarawa and Oyo was 3.2
compared to 3.8 in the additional four states at the 9-month survey (p-value 0.01). In addition, fewer PPMVs in
Bauchi, Cross River, Ebonyi and Kaduna incorrectly reported side effects as adverse and severe adverse events
during the follow-up surveys and monitoring visits. For example, PPMVs in Nasarawa and Oyo frequently
reported common side effects (e.g. irregular bleeding, weight gain, spotting) as adverse events. This revealed
that many PPMVs confused normal side effects with the adverse events that should be reported. In Phase II,
only two PPMVs incorrectly reported side effects as adverse event.

PPMV training
Trainings were held in November 2015 in Nasarawa and Oyo, and in May and June 2017 in Bauchi, Cross River,
Ebonyi and Kaduna. PPMVs were trained to provide FP counseling and progestin-only injectable contraceptive services (counsel, sell, refer and administer). Master Trainers who were certified to lead FP trainings in
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Nigeria facilitated the trainings. The curriculum was based on a set of training materials developed by PATH
on DMPA-SC5 and FHI 360 on DMPA injections for public providers.6 The training included adult learning
methodologies such as role play, group discussion, and hands-on practice. PPMVs were trained to counsel and
screen clients using the World Health Organization’s Medical Eligibility Criteria (MEC) Wheel, the Population
Council’s Balanced Counseling Strategy Plus (BCS+) and FHI 360’s Checklist for Screening Clients Who Want
to Initiate DMPA (or NET-EN).
Based on learnings from Nasarawa and Oyo, PPMVs were given job aids at the end of the trainings in Bauchi,
Cross River, Ebonyi and Kaduna to ensure they could properly screen and counsel clients. Each PPMV was
given a WHO MEC wheel, a copy of the BCS+ cards, and the FHI 360 DMPA screening checklist. During
the stakeholders meeting to review the curriculum, the FHI 360 DMPA screening checklist was simplified to
ensure that PPMVs with all levels of education could correctly screen clients interested in using the injectable.
PPMVs in the Bauchi, Cross River, Ebonyi, and Kaduna were given job aids during the training and were asked
about their use of job aids during the 9-month survey. The majority of PPMVs (86%) reported using the job
aids with some to all of their clients when providing FP services (data not shown). Among those who reported
using job aids with their clients (n=168), 78 percent reported using the WHO MEC Wheel, 70 percent reported
using BCS+, and 46 percent reported using the FHI 360 screening checklist.

Monitoring and supervision
A monitoring team comprised of the research staff, a Master Trainer, and key stakeholders visited PPMVs in
their shops after the training. The purpose of the monitoring visits was to: (1) observe the quality of injectable
services offered by PPMVs, especially drug storage and disposal of sharps; (2) provide support and mentorship
to PPMVs; and (3) provide stakeholders an opportunity to see the study’s progress, discuss implementation
challenges and solutions with PPMVs, and see what would be needed to broaden this program in their state.
The monitoring team used a form that included questions on the implementation challenges faced by PPMVs
and questions similar to those on knowledge and service provision in the follow-up survey.
In Nasarawa and Oyo, each PPMV was visited one, three and nine months after the training. The monitoring
team consisted of members from the research team, a Master Trainer, and federal, state and local ministry of
health staff, and a NAPPMED representative. Based on the monitoring team’s observations, and overall results
from Nasarawa and Oyo, some changes were made to the monitoring visits conducted in Bauchi, Cross River,
Ebonyi and Kaduna. First, a PCN representative in the project state was included in the monitoring team.
This was to ensure that PCN as the regulatory body for PPMVs, could observe PPMVs progress and provide
guidance on implementation challenges. Second, PPMVs were monitored one and six months after the training.
This reduced the total number of monitoring visits from three to two to avoid duplication with other data collection activities. Third, PPMVs were asked to role play administering DMPA-IM and DMPA-SC in front of
the Master Trainer. The Master Trainer assessed PPMVs’ skills using the observation checklist used at the posttest. Fourth, the monitors answered questions related to their observations of the PPMV’s shop to understand
whether PPMVs were properly storing and disposing sharps and keeping records of injectable clients.

5 https://www.path.org/resources/dmpa-sc-training-materials/
6 https://www.fhi360.org/sites/default/files/media/documents/checklist-dmpa-english.pdf
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Results
A total of 388 PPMVs participated in the five-day training. Seven PPMVs were dropped after the training
because they either did not demonstrate competence in injectable administration by the end of the training
or did not participate in all the sessions. This brought the total sample size to 381. In Nasarawa and Oyo,
four PPMVs were unavailable for the post-test survey, which took place one month after the training.7 By the
9-month survey, 38 PPMVs were either dropped from the study or were unavailable at the time of data collection. This brought the total sample for the
9-month survey to 343. Analyses were con- TA B L E 1 . PPMV C H A RAC TERIS TIC S AT PRETES T SU RVEY
ducted cross-sectionally and included data (N=381)
from all PPMVs interviewed at each respecPercentage
tive survey time-point.
Sex

PPMV characteristics and
family planning services
provided before the training
Table 1 shows the characteristics of PPMVs
enrolled in the study at the pretest survey.
Enrolled PPMVs were a diverse group of service providers. The majority (72%) were male,
67 percent were between 30 and 49 years of
age, and 92 percent had at least a secondary
education. Twenty-eight percent had previously worked in a health facility and only 21
percent had been working as a PPMV for less
than five years. Two-thirds of PPMVs (74%)
reported that their shops were open seven
days a week.
At the pretest survey, PPMVs were asked the
FP methods that they knew, the types of FP
methods they sold, and types of injectable
contraceptive services that they provide. Table
2 shows PPMVs’ unprompted responses to
FP knowledge. The majority of PPMVs knew
about the male condom (93%), the pill (90%),
and the injectable (86%). Only 28 percent
knew of emergency contraceptives and less
than a quarter could name the IUD (23%) the
implant (24%), or the vaginal ring (24%). Fewer
7 In Nasarawa and Oyo, the post-test survey was conducted one month after the training. For the purposes
of the analysis, these data were combined with post-test
data from Bauchi, Cross River, Ebonyi and Kaduna.
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Male

71.9

Female

28.1

Age
17 - 29

19.7

30 - 39

41.7

40 - 49

25.5

50+

13.1

Highest level of education
Primary school

8.4

Secondary school (WASC/GCE)

44.4

Two years of post-secondary (OND/NCE)

25.7

College degree (HND/1st degree)

16.3

Post graduate degree/other

5.2

Years working as a PPMV
Less than 5

20.5

5-9

20.7

10 - 14

19.9

15 or more

38.9

Have previously worked in a health facility
Yes

27.8

No

72.2

Number of days PM shop is open
7

73.8

6

24.9

5 or fewer

1.3

State
Bauchi

15.0

Cross River

13.1

Ebonyi

15.7

Kaduna

20.0

Nasarawa

20.0

Oyo

21.0

TA B L E 2 . PPMV K N OW L E D G E O F C O N TR AC EPTIVE
M E T H OD S AT PRE TE S T SURV E Y ( N = 3 81 )
Contraceptive Method

Percentage

Tubal ligation

5.1

Vasectomy

9.9

Pill

90.3

IUD/Loop

22.8

Injectables

86.1

Implant (n=225)†

23.6

Vaginal ring

23.6

Male condom

93.2

Female condom

61.7

Emergency contraception

28.1

Diaphragm

Almost all PPMVs (92%) provided at least one injectable contraceptive service at the pre-test survey.
Results in Figure 2 show that approximately 60 percent reported they counsel clients on injectable use, sell
injectable methods or refer clients to the nearest health
facility for injectable services. Forty-seven percent said
they administer injectable contraceptives in their shop.
Figure 3 shows the type of injectable contraceptive
methods sold by PPMVs in their shops. PPMVs primarily sold Depo-Provera (58%) and Noristerat (45%).
Less than two percent reported selling Cyclofem,
Mesigyna, or Sayana Press before the training.

7.6

Spermicide

5.5

Cycle beads

41.7

Withdrawal

11.8

Rhythm method

6.8

could name a permanent method: tubal ligation (5%)
and vasectomy (10%). PPMVs were asked which FP
methods they sold in their shops (Figure 1). PPMVs’
knowledge of FP methods seemed to correspond with
the type of FP methods that they sold. The three most
commonly sold FP methods were the pill (87%), male
condoms (75%) and injectable contraceptives (59%).

†
Only asked of PPMVs in Bauchi, Cross River, Ebonyi and
Kaduna

FIGU R E 1 . C O N TRAC E PTIV E ME TH O D S SO L D BY PP MVs AT PRETES T SURVEY (N=381)
100%

87.4
75.1

75%

59.3
50%

35.2
25%

0%

Pill

Injectables

Male
condoms

Female
condoms

3.9

1.6

IUD/Loop

Implant

1.1

1.6

Diaphragm Spermicide

FIGU R E 2 . IN J E C TA B L E C O N TRAC E PTIV E SERVIC ES PROVID ED BY P PMVs AT
PR E T E S T S U RV E Y ( N = 3 81 )
0%

25%

50%

Refer to health facilities/hospitals

75%

61.7

Sell injectable methods

60.1

Counsel on injectable use

59.8

Administer injectable onsite
None

100%

46.7
7.6
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FIGU R E 3 . T Y PE O F C O N TRAC E PTIV E METH O D S SO L D BY
PPM Vs AT PRE TE S T SURV E Y ( N = 3 81 )
0%

25%

50%

Depo-Provera

100%

75%

58.0

PPMVs can administer
injectable contraceptives
safely

The observation checklist for PPMV administration of DMPA-IM and DMPA-SC was
Cyclofem 2.1
conducted in Bauchi, Cross River, Ebonyi
and Kaduna immediately after the training
Mesigyna 1.3
and during the 1- and 6-month monitoring
Sayana Press 1.2
visits. The majority of PPMVs from these
states demonstrated key steps for safe
administration of injectable contraceptives, even six months after the training. Figure 4 shows the proportion
of PPMVs who demonstrated the key DMPA-IM administration steps during the post-test and 1-month monitoring visit. Results show that at least 75 percent of PPMVs demonstrated nine key steps for safe administration
of DMPA-IM after the training (n=225). There were slight decreases for all but one of the steps at the 1-month
monitoring visit (n=196). Only for one DMPA-IM step, pierce top of vial with sterile needle and fill syringe, was there
no difference observed from post-test to the 1-month visit (94% compared to 95%). Even though most of
these decreases were statistically significant, at least 50 percent of PPMVs demonstrated each of the nine steps
at the 1-month monitoring visit.
45.1

Noristerat

PPMVs’ skills improved between the 1- and 6-month monitoring visits. Figure 5 shows changes in the proportion of PPMVs who demonstrated the key DMPA-IM administration steps at the 1- and 6-month monitoring visits. A greater number of PPMVs demonstrated six of the nine key DMPA-IM steps compared to the
1-month observation. For example, the proportion of PPMVs who checked for the expiration date increased from
74 percent at the 1-month monitoring visit to 87 percent at the 6-month monitoring visit (p-value ≤0.01). Only
the DMPA-IM step aspirate needle remained low at the 6-month monitoring visit (56%). Eighty-five percent of
PPMVs in Bauchi, Cross River, Ebonyi and Kaduna, however, named this step when asked during the 9-month
follow-up survey (data not shown).

FIGUR E 4 . C OM PA R I SO N O F PPM V D E M O N S TRATIO N O F KEY D MPA - IM A D MINIS TRATIO N S TEPS AT
POS T-TES T A ND 1-M ON TH MO N ITO RIN G V ISIT †
100%

75%

94.2

93.0

91.6

80.1

94.2 94.9

91.6

82.7
73.5

91.1

95.6

91.1

77.0

74.7
59.2

50%

74.0
53.6

58.2

25%

0%

†
*

Wash hands**

Clean the
injection site**

Check expiration
date**

Rock gently
to mix**

Pierce vial with
sterile needle
and fill syringe

Observations used for PPMVs in Bauchi, Cross River, Ebonyi and Kaduna
p-value ≤0.05; **p-value ≤0.01
Post-test (n=225)
1-month monitoring visit (n=196)
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Expel air from
syringe**

Aspirate
needle**

Apply pressure Dispose needle
on injection site** in sharps box**

F IGUR E 5 . C OM PA R ISO N O F PPM V D E M O N S TRATIO N O F KEY D MPA - IM A D MINIS TRATIO N S TEPS AT
1-MO NT H M ON IT OR IN G V ISIT ( N = 1 9 6 ) AN D 6 - MO NTH MO NITO RING VIS IT †
100%

80.1 80.1

82.7

94.9

89.0

86.6
73.5

75%

77.0

100.0

86.6

84.2
71.8

69.5
59.2

58.2

53.6 56.1

50%

74.0

25%

0%

†

Wash hands

Clean the
injection site

Check expiration
date**

Rock gently
to mix**

Observations used for PPMVs in Bauchi, Cross River, Ebonyi and Kaduna
p-value ≤0.05; **p-value ≤0.01
1-month monitoring visit (n=197)

*

Pierce vial with
sterile needle and
fill syringe**

Expel air
from syringe*

Aspirate
needle

Apply pressure Dispose needle
on injection site** in sharps box*

6-month monitoring visit (n=164)

Figure 6 shows the proportion of PPMVs who demonstrated the key DMPA-SC administration steps during
the post-test and 1-month monitoring visit. As seen with DMPA-IM, most PPMVs (79%) demonstrated the
nine key steps for DMPA-SC administration at post-test. There was a decrease, however, in the proportion of
PPMVs who demonstrated seven of the nine key DMPA-SC steps at the 1-month monitoring visit (n=196).
There were only two DMPA-SC steps, check expiration date (91% to 100%, p-value ≤0.01) and activate the Uniject™
(82% to 89%, p-value ≤0.05), where the proportion of PPMVs who named these steps increased from post-test
to 1-month monitoring visit.
A greater number of PPMVs demonstrated six of the nine key DMPA-SC steps at the 6-month monitoring
visit compared to the 1-month monitoring visit (Figure 7). For example, when demonstrating the DMPA-SC
steps, the proportion of PPMVs who inserted the Uniject straight into skin at a slight downward angle increased from
49 to 85 percent (p-value ≤0.01). At the 6-month monitoring visit, at least 75 percent of PPMVs demonstrated
the key DMPA-SC steps.

F IGUR E 6 . C OM PA R ISO N O F PPM V D E M O N S TRATIO N O F KEY D MPA - S C A D MINIS TRATIO N S TEPS AT
POS T-TE S T A ND 1-M O N TH M O N ITO RIN G V ISIT †
100%

92.0

91.1
80.1

75%

100.0

78.7

88.4
78.1

82.2

89.3

92.0

68.4

66.3
52.6

50%

98.2

93.8

92.4

69.9

48.9

25%

0%

†
*

Wash hands**

Clean the
Check expiration
injection site**
date**

Shake
vigorously to
mix**

Activate
Uniject*

Pinch skin at
injection site**

Insert at slight
Squeeze
Dispose Uniject
reservoir slowly** in sharps box**
downward
angle**

Observations used for PPMVs in Bauchi, Cross River, Ebonyi and Kaduna
Post-test (n=225)
1-month monitoring visit (n=196)
p-value ≤0.05; **p-value ≤0.01
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F IGURE 7. C OM PA R ISO N O F PPM V D E M O N S TRATIO N O F KEY D MPA - SC A D MINIS TRATIO N S TEPS AT
1-MON T H A N D 6 -M ON TH MO N ITO RIN G V ISIT S †
100.0 100.0

100%

75%

80.1 82.3

78.1

75.0

96.9

89.3 92.1

86.6

84.8
66.3

75.6

52.6

50%

81.7
68.4

69.9

48.9

25%

0%

†
*

Wash hands**

Clean the
injection site**

Check expiration
date**

Shake
vigorously to
mix**

Activate
Uniject*

Pinch skin at
injection site**

Insert at slight
Squeezes
Dispose Uniject
downward
reservoir slowly** in sharps box**
angle**

Observations used for PPMVs in Bauchi, Cross River, Ebonyi and Kaduna

p-value ≤0.05; **p-value ≤0.01

1-month monitoring visit (n=196)

6-month monitoring visit (n=164)

Figure 8 presents the monitoring teams’ observations
of PPMVs and their shop during the 1- and 6-month
monitoring visits. Almost all PPMVs in Bauchi, Cross
98.2
River, Ebonyi and Kaduna were observed having a
100%
97.5
sharps disposal box in their shop at the 1-month and
82.9
75%
69.9
6-month monitoring visits (98% each). There was
an increase in the proportion of PPMVs who were
50.0
50%
observed properly storing the drugs in their shop
from 70 percent at the 1-month monitoring visit to
25%
21.0
83 percent at the 6-month monitoring visit (p-value
≤0.01), and those who kept injectable record form
0%
Sharps box
Drugs stored PPMV had injectable
21 percent at the 1-month monitoring visit to 50 peron site**
record for ms
onsite
**
cent at the 6-month monitoring visit (p-value ≤0.01).
completed
One reason why only half of PPMVs kept injectable
1-month monitoring visit (n=196)
6-month monitoring visit (n=164)
Observations used for PPMVs in Bauchi, Cross River, Ebonyi and Kaduna
record forms may have been due to police and regup-value ≤0.05; p-value ≤0.01
latory harassment, despite being authorized to provide injectable contraceptives under the study. During
the monitoring visits, many PPMVs cited police harassment for why they did not keep up-to-date records.
Regulatory and police representatives periodically visit patent medicine shops to ensure PPMVs are not selling
unauthorized commodities, or for extortion. This may explain why some PPMVs reported that they did not
keep records of their injectable contraceptive services.
FIGU R E 8. C O MPARISO N O F MO N ITO RING TEA M
OB S E RVAT IO N S O F PPM V s ’ PRAC TIC E S AT
1-M ON T H A N D 6 - MO N TH MO N ITO RIN G V ISIT S †

†
*

**

Most PPMVs administered injectable contraceptives to at least one client monthly. Eighty-seven percent of
PPMVs in all six states (n=318) reported they had administered an injectable contraceptive to at least one
client in the 30 days preceding the 3-month follow-up survey and 92 percent reported they had administered
an injectable contraceptive to at least one client in the 30 days preceding the 9-month follow-up survey. At the
9-month survey, the average number of injections provided in the previous 30 days was 2.4 for DMPA-IM,
1.3 for NET-EN and less than 1 for DMPA-SC (data not shown). No adverse events were reported over the
course of the study.
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There was no difference in knowledge and skills between PPMVs with and
without previous health facility experience
PPMVs were asked a series of unprompted questions to ascertain their knowledge on injectable contraceptives.
Specifically, PPMVs were asked about the knowledge needed for counseling (side effects), screening (exclusionary health conditions), and providing injectable contraceptives (when a woman can start the injectable,
post-administration instructions for clients, and needle safety practices). The results in Table 3 show there
were no differences between those who had and who had not previously worked in a health facility for most of
the knowledge indicators. At the post-test survey, there were statistically significant differences in knowledge
for only 8 of 41 indicators. For example, 76 percent of PPMVs who had worked in a health facility named
dizziness as a side effect compared to 62 percent of PPMVs who had not worked in a health facility (p-value ≤0.05).
Interestingly, PPMVs who had not previously worked in a health facility demonstrated higher knowledge for
two of those eight indicators. Forty percent of PPMVs who had not worked in a health facility named current or
history of stroke and 35 percent named liver tumor as exclusionary health conditions compared to only 26 percent
and 20 percent of PPMVs who had worked in a health facility (p-value ≤0.05; p-value ≤0.01). There were no
differences in knowledge of the nine method characteristic indicators (reinjection frequency, injection device,
and administration location on the body) for DMPA-IM, NET-EN and DMPA-SC between the two groups
(data not shown).
TAB L E 3 . C OM PARIS O N O F PPMV IN J E C TA B L E KNOWL ED GE A MO NG TH O SE WH O H A D A ND H A D NOT
PRE VI OU S LY WO RK E D IN A H E ALTH FAC IL IT Y, PO S T-TES T S URVEY †
PPMVs who had previously
worked in a facility (n=95)

PPMVs who had not previously
worked in a facility (n=203)

Percentage

What are the common side effects of the injectable?
Change in menstruation

96.8

91.6

Headache

85.3

84.2

Weight gain

64.2

55.7



Dizziness*

75.8

62.1

Delayed return to fertility

27.4

24.6

Temporary mild/moderate skin irritation**

40.0

18.7

Decrease in sex drive

22.1

21.2

Under what health conditions should a woman NOT be provided the injectable?
High blood pressure (160/100)*

82.1

70.4

History of breast cancer

65.3

70.0



Diabetes

61.1

62.6

Current/history of stroke or ischaemic heart disease*

26.3

40.4

Multiple risk factors for cardiovascular disease

40.0

37.0

Liver tumor

20.0

35.0

Unexplained vaginal bleeding

38.9

32.0

Breastfeeding up to 4/6‡ weeks postpartum

25.3

18.7

Rheumatic disease

15.8

19.7

Migraines with aura worsening with injectable use

14.7

16.3

7.4

11.8

When she is not pregnant

67.4

56.7

4/6 weeks after childbirth

66.3

63.1

Within 1st 7 days of a menstrual cycle w/out back-up method

31.6

**

Deep vein thrombosis

When can a woman start the injectable method?
‡

30.1

con’t on next page
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PPMVs who had previously
worked in a facility (n=95)

PPMVs who had not previously
worked in a facility (n=203)

Percentage
After 1st 7 days of a menstrual cycle w/ back-up method

27.4

37.0

Immediately after a miscarriage or abortion*

29.5

19.2

Immediately after stopping another method*

30.5

17.7

What instructions should be provided to women after administering the injection?
When to return for next injection

90.5

96.1

Do not rub the injection site

70.5

60.1

Provide information about possible side effects

64.1

58.1

Go to health facility if concerns/questions about the method

10.5

9.4

Go to health facility if any significant changes in health

17.9

17.2

Go to health facility if suspicion about pregnancy

11.6

7.9

Don’t touch the needles

75.8

72.9

Don’t recap the needle

71.6

68.0

Discard needle immediately after use**

80.0

61.6

Ensure sharps are disposed of in sharps box

72.6

68.5

Don’t overfill sharps box

42.3

35.5

What are the ways to handle needles/syringes safely?

What precautions should be taken to prevent infection from a needle stick injury?
Wash hands with soap and water immediately

75.8

69.0

Use sharps box for needles and sharps

60.0

56.2

Handle needles carefully

63.2

58.1

Wash wound with soap and water

85.3

86.2

Ensure nothing is put on wound site after cleaning it

25.3

17.7

Apply plaster bandage to wound site

11.6

5.4

What should be done in the case of a needle stick injury?

p-value ≤0.05; **p-value ≤0.01
Comparisons used for PPMVs in all states except Oyo due to respondent ID error
‡
The WHO guidelines for injectable use and breastfeeding were updated during the study’s implementation. PPMVs in the first two states were trained
using the 6-week standard and PPMVs in the additional four states were trained using the 4-week standard.
*
†

Similar trends were observed at the 9-month follow-up survey (Table 4). Results shows that there were no
significant differences in (a) knowledge of injectable side effects, (b) how to handle needles safely, (c) how to
prevent infection from a needle stick injury, or (d) what should be done in case of a needlestick injury among
those who had and had not previously worked in a health facility. Of the 41 knowledge indicators, PPMVs who
had previously worked in a health facility demonstrated higher knowledge for only four of those indicators:
(1) diabetes as an exclusionary health condition; (2) a woman can start the injectable within first seven days of her
menstrual cycle without a back-up method; (3) when to return for the next injection; and, (4) provide information about possible
side effects as post-administration information for clients.
TA B L E 4 . C OM PARIS O N O F PPMV IN J E C TA B L E KNOW L ED GE A MO NG TH O SE W H O H A D A ND H A D NOT
PRE VI OU S LY WO RK E D IN A H E ALTH FAC IL IT Y, 9- MO NTH FO L LOW - UP SURVEY †
PPMVs who had previously
worked in a facility (n=84)

PPMVs who had not previously
worked in a facility (n=181)

Percentage

What are the common side effects of the injectable?
Change in menstruation

90.5

90.6

Headache

85.7

81.2

Weight gain

81.0

71.8
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PPMVs who had previously
worked in a facility (n=84)

PPMVs who had not previously
worked in a facility (n=181)

Percentage


Dizziness

57.1

57.5

Delayed return to fertility

17.9

17.7

Temporary mild/moderate skin irritation

34.5

24.9

Decrease in sex drive

23.8

20.4

High blood pressure (160/100)*

67.9

63.5

History of breast cancer

52.4

57.5

Diabetes**

82.1

63.0

Under what health conditions should a woman NOT be provided the injectable?



Current/history of stroke or ischaemic heart disease

33.3

27.6

Multiple risk factors for cardiovascular disease

22.6

28.7

Liver tumor

29.8

27.1

Unexplained vaginal bleeding

31.0

27.1

Breastfeeding up to 4/6 weeks postpartum

29.8

24.9

Rheumatic disease

4.8

8.9

Migraines with aura worsening with injectable use

22.6

16.6

Deep vein thrombosis

16.7

15.5

‡

When can a woman start the injectable method?
When she is not pregnant

82.1

72.4

4/6‡ weeks after childbirth

66.7

58.0

Within 1st 7 days of a menstrual cycle w/out back-up method**

54.8

37.6

After 1st 7 days of a menstrual cycle w/ back-up method

26.2

37.0

Immediately after a miscarriage or abortion

23.8

18.8

Immediately after stopping another method

15.5

12.7

What instructions should be provided to women after administering the injection?
When to return for next injection*

96.4

88.4

Do not rub the injection site

72.6

63.0

Provide information about possible side effects*

76.2

63.0

Go to health facility if concerns/questions about the method

3.6

9.9

Go to health facility if any significant changes in health

26.2

20.1

Go to health facility if suspicion about pregnancy

13.1

6.6

What are the ways to handle needles/syringes safely?
Don’t touch the needles

81.0

78.5

Don’t recap the needle

81.0

79.0
58.6

Discard needle immediately after use

54.8

Ensure sharps are disposed of in sharps box

71.4

75.1

Don’t overfill sharps box

17.9

18.8

What precautions should be taken to prevent infection from a needle stick injury?
Wash hands with soap and water immediately

81.0

Use sharps box for needles and sharps

62.4

68.0
67.9

Handle needles carefully

78.6

71.8
85.6

What should be done in the case of a needle stick injury?
Wash wound with soap and water

82.1

Ensure nothing is put on wound site after cleaning it

28.6

21.0

Apply plaster bandage to wound site

15.5

15.5

p-value ≤0.05; **p-value ≤0.01
Comparisons used for PPMVs in all states except Oyo due to respondent ID error
‡
The WHO guidelines for injectable use and breastfeeding were updated during the study’s implementation. PPMVs in the first two states were trained
using the 6-week standard and PPMVs in the additional four states were trained using the 4-week standard.
*
†
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Figures 9, 10, 11 and 12 show the differences in PPMV demonstration of key DMPA-IM and DMPA-SC
administration steps between those with and without health facility experience at the post-test and 6-month
monitoring visits. As seen with the knowledge indicators, PPMVs without health facility experience demonstrated comparable skills for DMPA-IM and DMPA-SC administration to those with health facility experience
at both time points. For example, only for two DMPA-IM steps, withdraw contents and expel air from the syringe and
aspirate needle, and one key DMPA-SC step, check expiration date, did a significantly higher proportion of PPMVs
with health facility experience demonstrate these steps compared to those without health facility experience
at the post-test observation (Figures 9 and 10). At the 6-month monitoring visit, however, there were no
differences for eight of the nine key DMPA-IM steps and seven of the nine DMPA-SC steps. For the steps
where there were significant differences, a higher proportion of PPMVs without health facility experience
demonstrated these steps (dispose of needle for DMPA-IM and guide client to select injection site and activate Uniject for
DMPA-SC) compared to those with health facility experience (Figures 11 and 12).
F IGUR E 9 . C OM PA R I SO N O F PPMV D E M O N S TRATIO N O F KEY D MPA - IM A D MINIS TRATIO N S TEPS A MO NG
THO SE W H O H A D A N D H A D N OT PRE V IO US LY WORKED IN A H EA LTH FAC IL IT Y, PO S T-TES T
100%

98.5

95.5

92.4

92.4

92.4 91.1

98.5

91.0 91.8

92.4

100.0

95.5

89.6

87.3

75%

89.2

98.5 94.3

68.4

50%

25%

0%

†
*

Wash hands

Clean the
injection site

Check expiration
date

Rock gently
to mix

Observations used for PPMVs in Bauchi, Cross River, Ebonyi and Kaduna
p-value ≤0.05; **p-value ≤0.01
Had previously worked in a facility (n=67)

Pierce vial with
sterile needle
and fill syringe

Aspirate
needle**

Expel air from
syringe**

Apply pressure on
injection site

Dispose
needle in
safety box

Had not previously worked in a facility (n=158)

F IGUR E 10. C OM PA R ISO N O F PPM V D E M O N S TRATIO N O F KEY D MPA - S C A D MINIS TRATIO N S TEPS A MO N G
THO SE W H O H A D A N D H A D N OT PRE V IO US LY WORKED IN A H EA LTH FAC IL IT Y, PO S T-TES T
100%

92.5 91.8

75%

97.0
82.1

88.6

91.0

87.3

77.2

92.5 91.8

89.6

92.5 92.4

95.5 93.0

98.5 98.1

79.1

50%

25%

0%

†
*

Wash hands

Clean the
Check
Shake vigorously
injection site expiration date*
to mix

Observations used for PPMVs in Bauchi, Cross River, Ebonyi and Kaduna
Had previously worked in a facility (n=67)
p-value ≤0.05; **p-value ≤0.01
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Activate
Uniject

Pinch skin at
injection site

Squeezes
Insert at slight
Dispose Uniject
downward
reservoir slowly in safety box
angle

Had not previously worked in a facility (n=158)

F IGUR E 1 1 . C OM PA R ISO N O F PPMV D E M O N S TRATIO N O F KEY D MPA - IM A D MINIS TRATIO N S TEPS A MO N G
T HOSE W H O H A D A ND H AD N OT PRE V IO US LY WORKED IN A H EA LTH FAC IL IT Y, 6- MO NTH MO NITO RING VISIT
100.0 100.0

100%

87.2

82.1

83.0

91.5

83.0

88.0

89.4

88.9

85.5

75%

68.1 70.1

66.0

74.4

72.3

55.3 56.4
50%

25%

0%

†
*

Wash hands

Clean the
injection site

Check expiration
date

Rock gently
to mix

Observations used for PPMVs in Bauchi, Cross River, Ebonyi and Kaduna
p-value ≤0.05; **p-value ≤0.01
Had previously worked in a facility (n=47)

Pierce vial with
sterile needle
and fill syringe

Expel air from
syringe

Aspirate
needle

Apply pressure on
injection site

Dispose needle
in safety box**

Had not previously worked in a facility (n=117)

F IGUR E 1 2 . C OM PA R ISO N O F PPM V D E M O N S TRATIO N O F KEY D MPA - SC A D MINIS TRATIO N S TEPS A MO N G
T HOSE W H O H A D A ND H AD N OT PRE V IO US LY WORKED IN A H EA LTH FAC IL IT Y, 6- MO NTH MO NITO RING VISIT
100%

98.5

92.4

95.5

92.4

92.4 91.1

91.0 91.8

98.5

92.4

100.0
87.3

75%

95.5

89.6

89.2

98.5 94.3

68.4

50%

25%

0%

†
*

Wash hands

Clean the
injection site

Check expiration
date

Rock gently
to mix

Observations used for PPMVs in Bauchi, Cross River, Ebonyi and Kaduna
p-value ≤0.05; **p-value ≤0.01
Had previously worked in a facility (n=67)

Pierce vial with
sterile needle
and fill syringe

Expel air from
syringe**

Aspirate
needle**

Apply pressure on
injection site

Had not previously worked in a facility (n=158)

PPMVs knowledge of injectable contraceptive characteristics was higher
after the training and was retained nine months after the training
Knowledge increased from the pretest to post-test survey
PPMVs were asked a series of unprompted questions to ascertain their knowledge on injectable contraceptives
during the pre-, post- and 9-month surveys. Significant increases in PPMVs’ knowledge related to counseling,
screening and administration of the injectable contraceptive method were observed on 47 of 50 knowledge
indicators from the pretest to post-test survey. Knowledge doubled for 32 indicators and increased by at least
half for eight indicators. Despite these increases, knowledge remained below 50 percent for 21 indicators at the
post-test survey.
Figure 13 shows PPMV knowledge of seven common side effects of the injectable method at the pretest and
post-test surveys. At the pretest survey, less than one-third of PPMVs spontaneously named headache (23%),
weight gain (32%), dizziness (19%), delayed return to fertility (8%), temporary skin irritation (1%) or decrease in sex drive

THE EVIDENCE PROJECT

21

Dispose
needle in
safety box

(2%) as common side effects of the injectable method. At the post-test survey, knowledge on all seven common
side effects increased significantly. Larger increases were seen for: (1) change in menstruation from 64 percent to 93
percent; (2) headache from 23 percent to 79 percent; (3) weight gain from 32 percent to 60 percent; and (4) dizziness
from 19 percent to 56 percent. For the remaining three side effects, the percentage point increases in knowledge
at post-test were not as large and knowledge remained low at approximately 20%.
FIGU R E 1 3. K N OW L E D G E C O MPARISO N S O F SEVEN C O MMO N S ID E EF F EC T S O F TH E INJ EC TA BLE AT
PR E T E S T A N D PO S T-TE S T SU RV E YS †
100%

92.8

Pretest (n=381)
Post-test (n=377)

78.5

75%

64.0

60.2

56.0

50%

32.0
23.4

25%

22.8

18.9

20.9

8.4
0%

†
*

Change in
menstruation**

Headache**

Weight gain**

Dizziness**

18.0
1.8

0.5

Delayed return
to fertility**

Temporary mild
skin irritation**

Decrease in sex
drive**

Post-training surveys asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
p-value ≤0.05; **p-value ≤0.01

Figure 14 shows that pretest and post-test survey results of 11 exclusionary health conditions of the injectable
contraceptive. At the pretest survey, 41 percent of PPMVs named high blood pressure as an exclusionary health
condition. Fewer spontaneously named any of the other health conditions8, ranging from 19 percent saying diabetes to 3 percent migraines with aura or deep vein thrombosis. At the post-test survey, knowledge on all 11 exclusionary
health conditions increased significantly, yet eight health conditions were mentioned by fewer than 50 percent.

FIGUR E 1 4 . KN OW L E D G E C O MPARIS O N S O F 1 1 E XC LUSIO NA RY H EA LTH C O ND ITIO NS O F TH E INJ EC TA B L E
AT PR ET ES T A ND POS T-T E S T S U RV E YS †
100%

Pretest (n=381)

50%

Post-test (n=377)

73.5

75%

65.3

59.7

40.2

36.6

25%

30.2

29.7

21.2

19.2
7.9

6.4
0%

36.1

High blood
pressure
(160/100)**

Breast
cancer**

Diabetes**

7.4

Stroke or
At risk for
ischaemic heart cardiovascular
**
disease
disease**

9.7

Live tumor**

9.9

Unexplained
vaginal
bleeding**

8.9

Breastfeeding up
to 4/6‡ weeks
postpartum**

19.1
3.9

Rheumatic
disease**

18.8
3.2

Migraines with
aura**

13.0
2.6

Deep vein
thrombosis**

Post-training surveys asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
The WHO guidelines for injectable use and breastfeeding were updated during the study’s implementation. PPMVs in the first two states were trained using the 6-week standard and PPMVs in the additional
four states were trained using the 4-week standard.
*
p-value ≤0.05; **p-value ≤0.01
†

‡

8 For the purposes of the study, PPMVs were authorized to administer clients were in category one based on the WHO Medical Eligibility
Criteria.
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Figure 15 presents PPMVs’ knowledge of when a woman can begin the injectable. At the pretest survey, only
33 percent of PPMVs said if she is not pregnant and 19 percent said within the first seven days of her menstrual cycle
without a back-up method for when a woman can start the injectable. At the post-test survey, these two indicators increased to 58 percent and 41 percent, respectively. Statistically significant increases in knowledge were
observed for all knowledge indicators in Figure 15 except after first seven days of a menstrual cycle with back-up method.
After the training, few PPMVs spontaneously recalled that the injection could be used immediately after a miscarriage or abortion (18%) or immediately after stopping another method (18%).
FIGU R E 1 5 . K N OW L E D G E C O M PARIS O N S O F WH EN A WO MA N CA N S TA RT TH E INJ EC TA B L E AT
PR E T E S T A N D PO S T-TE S T SURV E YS †
100%

Pretest (n=381)
Post-test (n=377)

75%

59.4

58.1
50%

41.1

33.0
25%

0%

32.3 32.4
13.9

19.4

18.0

17.5

1.8

When she is not
pregnant**

4/6‡ weeks after
childbirth**

Within 1st 7 days
of a menstrual
cycle w/out
back-up method**

After 1st 7 days of
a menstrual cycle
w/ back-up
method

Immediately
after a
miscarriage or
abortion**

1.6

Immediately after
stopping another
method**

Post-training surveys asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
The WHO guidelines for injectable use and breastfeeding were updated during the study’s implementation. PPMVs in the first two states
were trained using the 6-week standard and PPMVs in the additional four states were trained using the 4-week standard.
*
p-value ≤0.05; **p-value ≤0.01
†
‡

Figure 16 shows PPMV responses to the information that should be offered to clients after receiving an
injectable. Across the six indicators at the pretest survey, the proportion of PPMVs who knew this information
ranged from 40 percent for when to return for the next injection to 5 percent for going to health facility for significant
changes in health. At the post-test survey, nearly all (92 %) of PPMVs knew to tell their client when to return for their
next injection. Roughly two-thirds (66%) of PPMVs knew to tell their client not to rub the injection site and more than
half (60 %) knew to provide information about possible side effects. Fewer PPMVs, however, said that clients should
go to the health facility if significant changes in health (15%), go to health facility if concerns/questions about methods (9%), or
to go to the health facility if suspicion of pregnancy (7%). When comparing these results to client responses in Figure
26, 91 percent of clients reported the PPMV told them what to do if they had a problem with the injectable
at their first injection (n=561). Eighty-seven percent of clients reported they were instructed to return to the
PPMV if they experienced any problems (data not shown).
Despite knowledge gains for 29 of the 30 indicators listed in Figures 13-16, knowledge remained low for some
indicators. However, most PPMVs (86%) in Bauchi, Cross River, Ebonyi, and Kaduna reported using job aids
with their clients, suggesting PPMVs may refer to job aids to assist in remembering long lists of information
(e.g. side effects and exclusionary health conditions) when providing injectable contraceptive services.
PPMVs were also asked about the characteristics of different injectable methods as shown in Figure 17. Results
show that key knowledge of DMPA-IM, DMPA-SC, and NET-EN9 was significantly higher at the post-test
9 Only PPMVs in the additional four states were asked questions about NET-EN.
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than at the pretest survey. The greatest increases in knowledge were observed for DMPA-SC because a small
proportion of PPMVs at pretest (5 %) knew about this method (data not shown). At the post-test survey, over
89 percent of PPMVs correctly named the (a) reinjection frequency, (b) at least one location on the body where
the injectable can be administered, and (c) the device used to administer each of the three injectable methods.
FIGU R E 16. K N OW L E D G E C O M PARIS O N S O F PO S T- A D MINIS TRATIO N INS TRUC TIO NS AT P RETES T
A ND POS T-T E S T SURV E YS †
0%

25%

91.5
13.9

Do not rub the injection site**

66.1
22.8

Provide information about possible side effects**

59.7
5.0
7.7

Go to health facility if any significant changes in health**

15.7

7.7
8.9

Go to health facility if concerns/questions about the method

Pretest (n=381)
Post-test (n=377)

5.3
7.2

Go to health facility if suspicion about pregnancy

*

100%

75%

40.2

When to return for next injection**

†

50%

Post-training survey asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
p-value ≤0.05; **p-value ≤0.01

FIGU R E 17. K N OW L E D G E C O M PARISO N S O F KEY INJ EC TA B L E METH O D C H A RAC TERIS TIC S AT
PR E T E S T A N D PO S T-TE S T SURV E YS †
DMPA-IM

Pretest (n=381)

0%

Post-test (n=377)

25%

50%

64.8

Injection device (syringe/needle)**

97.0
66.9

Injection frequency (3 months/13 weeks)**

99.0
72.7

Injection location (deltoid buttocks)**
NET-EN ‡

Pretest (n=225)

100.0

Post-test (n=225)

51.1

Injection device (syringe/needle)**

7.7

89.0
51.6

Injection location (deltoid or buttocks)**
Pretrest (n=381)

93.0
40.0

Injection frequency (2 months/8 weeks)**

DMPA-SC

100%

75%

98.0

Post-test (n=377)

Injection device (uniject)**
Injection frequency (3 months/13 weeks)**
Injection location (back of arm, abdomen or front of thigh)

**

2.4
7.7

93.0

2.6
97.0
3.2
100.0

Post-training surveys asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
Asked of PPMVs in Bauchi, Cross River, Ebonyi and Kaduna only
*
p-value ≤0.05; **p-value ≤0.01
†
‡
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To understand PPMVs knowledge of needle safety practices, PPMVs were asked: (1) how to handle needles
safely; (2) how to prevent infection from a needle stick injury; and (3) what to do in the event of a needle stick
injury. Table 5 presents these results. For most of the indicators, fewer than 50 percent of PPMVs displayed
knowledge before the training, but the percentage increased significantly after the training. For example, 72
percent of PPMVs at the post-test survey identified don’t recap needles as one way to handle needles safely compared to 36 percent at the pretest survey (p-value ≤0.01). Seventy-four percent at the post-test survey identified
wash hands before and after administration to prevent infection compared to 31 percent at the pretest survey (p-value
≤0.01). The percentage of PPMVs with knowledge remained low at the post-test survey for ensure nothing is in
the wound site (18 %) and decreased from 24 percent to 8 percent for apply plaster bandage to the wound site.
TA B L E 5 . KN OW L E D G E C O MPARIS O N S OF NEED L E SA F ET Y PRAC TIC ES AT PRETES T
A ND POS T-T E S T SU RV E YS †
Pre-test (n=381)

Post-test (n=377)

Percentages

What are the ways to handle needles safely
Don’t touch the needle**

48.6

74.0

Don’t recap the needle**

29.7

65.8

Discard needle immediately after use**

35.7

71.9

Ensure sharps are disposed of in sharps box**

32.6

69.8

Don’t overfill sharps box**

9.2

36.1

What precautions should be taken to prevent infection from needle stick injuries
Wash hands with soap and water immediately
before and after administering the injectable**

30.5

73.5

Use sharps box for needles and sharps**

35.7

59.7

Handle needles carefully

50.9

62.3

Wash wound with soap and water**

36.8

82.5

Ensure nothing is put on wound site after cleaning it

22.6

17.8

Apply plaster bandage to wound site

23.6

7.9

*

What should be done in the case of a needles stick injury

*
†

**

p-value ≤0.05; p-value ≤0.01
Post-training survey asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
**

Knowledge retention from post-test to 9-month follow-up survey
PPMVs retained knowledge of injectable contraceptive characteristics nine months after the training. Among
the 50 indicators used to measure knowledge, from the post-test survey to the 9-month follow-up survey,
knowledge increased for 13 of 50 indicators and was retained for 29 of 50 indicators. For 21 indicators, less
than 50 percent of PPMVs displayed knowledge at the post-test survey.
Figures 18, 19, 20 and 21 show knowledge comparisons between the post-test and 9-month surveys for
common side effects, exclusionary health conditions, when a woman can begin the injectable and post-administration instructions. Results show that there were no significant differences for most of the indicators between
the post-test and 9-month follow-up surveys. In some cases, knowledge increased. For example, in Figure 18
knowledge of weight gain as a side effect increased from 60 percent at the post-test to 74 percent at the 9-month
survey (p-value ≤0.01). In Figure 20, PPMVs who said a woman can start the injectable method when she is not
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pregnant increased from 58 percent to 73 percent, and within the first seven days of her menstrual cycle without a back-up
method increased from 41 percent to 55 percent (p-value ≤0.05).
There were few decreases in knowledge between the post-test and 9-month surveys. In Figure 18, fewer
PPMVs identified delayed return to fertility as a side effect at the 9-month survey (15 %) compared to the post-test
survey (23 percent, p-value ≤0.01). In Figure 19, fewer PPMVs named the following exclusionary health conditions at the 9-month survey compared to the post-test: history of breast cancer (65% vs. 44%), liver tumor (30%
vs. 23%), and rheumatic disease (19% vs. 6%).
Figure 22 shows that PPMVs’ knowledge of method-specific characteristics was the same between the posttest and 9-month surveys for six of the nine indicators. PPMVs’ knowledge of the correct injection device used
for DMPA-IM (syringe and needle) and for DMPA-SC (Uniject) increased from the post-test survey to 9-month
survey. For example, 100 percent of PPMVs correctly named Uniject as the injection device for DMPA-SC
compared to 93 percent at the post-test survey. Only for the DMPA-SC reinjection frequency (13 weeks) was
there a decrease in knowledge between the 9-month and post-test survey. Still, 92 percent of PPMVs correctly
named 13 weeks as the DMPA-SC re-injection frequency at the 9-month survey.

F IGUR E 1 8. KN OW L E D G E C O MPARISO N S O F SE V EN C O MMO N S ID E EF F EC T S O F TH E
INJECTA B L E AT POS T-TE S T † A N D 9 - MO N TH S U RV EYS
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Post-training surveys asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
p-value ≤0.05; **p-value ≤0.01
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Post-training surveyss asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
The WHO guidelines for injectable use and breastfeeding were updated during the study’s implementation. PPMVs in the first two states were trained using the 6-week standard and PPMVs in the additional four states were trained
using the 4-week standard.
*
p-value ≤0.05; **p-value ≤0.01
†
‡
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FIGU R E 20 . K N OW L E D G E C O M PARIS O N S O F W H EN A WO MA N CA N S TA RT TH E INJ EC TA B L E AT T HE
POS T-T E S T † A N D 9 - MO N TH S U RV E YS
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54.5

50%

41.1
32.4

25%

0%

29.5
18.0 17.8

When she is not
pregnant**

4/6‡ weeks after
childbirth

Within 1st 7 days
of a menstrual
cycle w/out
back-up method**

After 1st 7 days of
a menstrual cycle
w/ back-up
method

17.5

Immediately
after a
miscarriage or
abortion

12.5

Immediately after
stopping another
method

Post-training surveyss asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
The WHO guidelines for injectable use and breastfeeding were updated during the study’s implementation. PPMVs in the first two states
were trained using the 6-week standard and PPMVs in the additional four states were trained using the 4-week standard.
*
p-value ≤0.05; **p-value ≤0.01
†
‡

FIGU R E 21 . K N OW L E D G E C O M PARIS O N S O F PO S T- A D MINIS TRATIO N INS TRUC TIO NS AT TH E POS TT E S T † A ND 9 - MO N TH S U RV E YS
0%

25%

50%

75%

91.5
92.7

When to return for next injection
66.1
70.3

Do not rub the injection site
59.7
59.8

Provide information about possible side effects
Go to health facility if concerns/questions about the method

8.8
7.7
15.7

Go to health facility if any significant changes in health**
Go to health facility if suspicion about pregnancy
†
*

100%

27.1
7.2
7.3

Post-test (n=377)
9-month (n=343)

Post-training survey asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
p-value ≤0.05; **p-value ≤0.01

Table 6 presents changes in PPMVs’ knowledge of needle safety measures from the post-test and 9-month
surveys. PPMVs’ knowledge increased for many of the needle safety measures: a higher proportion of PPMVs
named wash hands with soap and water (72% compared to 60%, p-value ≤0.01) and handle needles carefully (80%
compared to 62%, p-value ≤0.01) as ways to prevent infection from needle stick injury at the 9-month survey.
Increases were also seen for three of five indicators to handle needles safely. Only for two indicators, discard
needle immediately after use and don’t overfill the sharps box, did the percentage of PPMVs with knowledge decrease
from the post-test to 9-month survey (20 and 21 percentage point decrease, respectively).
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FIGU R E 2 2 . K N OW L E D G E C O M PARIS O N S O F KEY INJ EC TA B L E METH O D C H A RAC TERIS TIC S AT POS TT E S T † A N D 9 - M O N TH S U RV E YS
DMPA-IM

Post-test (n=377)

0%

9-month (n=343)

25%

50%

75%

100%

Injection device (syringe/needle)

96.6
99.7

Injection frequency (3 months/13 weeks)

98.7
99.1
100.0
100.0

Injection location (deltoid or buttocks)
NET-EN ‡

Post-test (n=225)

9-month (n=194)

Injection device (syringe/needle)

92.9
94.3

7.7

88.9
93.8

Injection frequency (2 months/8 weeks)

97.8
96.4

Injection location (deltoid or buttocks)
DM PA-SC

Post-test (n=377)

9-month (n=343)

Injection device (uniject)

93.1
97.9

7.7

96.8
91.8

Injection frequency (3 months/13 weeks)

100.0
99.7

Injection location (back of arm, abdomen or front of thigh)

Post-training surveys asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
Asked of PPMVs in Bauchi, Cross River, Ebonyi and Kaduna only
*
p-value ≤0.05; **p-value ≤0.01
†
‡

TA B L E 6 . KN OW L E D G E C O M PARIS O N S OF NEED L E SA F ET Y PRAC TIC ES AT PO S T-TES T †
A ND 9-M ON TH SURV E YS
Post-test (n=377)

9-month (n=343)

Percentages

What are the ways to handle needles safely
Don’t touch the needle**

74.0

83.9

Don’t recap the needle**

65.8

84.3

Discard needle immediately after use**

71.9

51.9

Ensure sharps are disposed of in sharps box**

69.8

79.9

Don’t overfill sharps box**

36.1

14.9

What precautions should be taken to prevent infection from needle stick injuries
Wash hands with soap and water immediately before
and after administering the injectable

73.5

78.4

Use sharps box for needles and sharps**

59.7

72.3

Handle needles carefully

62.3

79.9

Wash wound with soap and water*

82.5

88.1

Ensure nothing is put on wound site after cleaning it

17.8

22.1

Apply plaster bandage to wound site

7.9

11.9

**

What should be done in the case of a needle stick injury

*
†

p-value ≤0.05; **p-value ≤0.01
Comparisons used for PPMVs in all states except Oyo due to respondent ID error
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Client characteristics at first injection
and contraceptive use dynamics over
time

TA B L E 7. C L IENT C H A RAC TERIS TIC S AT FIRS T
INJ EC TIO N (N=561) †
Percentage

Age

A total of 561 clients were contacted by telephone and
surveyed within five days of receiving their first injection from a trained PPMV. Table 7 presents client characteristics at the time of their first injection. The median
age of these clients was 30 years (data not shown), with
more than half between the ages of 25 and 39. Most
had at least some schooling (94%), and more than half
(70%) had a secondary education or higher. Most clients
were married or living with a partner (92%) and had at
least one child (94%). One-third (33%) did not want to
have any additional children, while slightly more than
one-quarter (28%) wanted to wait at least two years
before having their next child. Sixty percent of clients
were employed. Forty percent of respondents had gone
to the same PPMV for injectable services at least once
before this visit (data not shown).

15 – 19

Figure 23 presents the outcome of clients’ first visit to
a trained PPMV for injectable contraceptive services.
More than half had been using a contraceptive method
before this visit: 40 percent continued with the injectable
method and 19 percent switched from a different contraceptive method. Forty-two percent of clients began
a new episode of use.10 Of the 40 percent (n=224)
who continued using the injectable method, 65 percent
received DMPA-IM, 18 percent received NET-EN, and
15 percent received DMPA-SC. Two percent did not
know which method they received.

Zero

5.5

One

11.2

Two

23.0

11.1

25 – 29

31.4

30 – 34

22.3

35 – 39

21.4

40 – 44

9.1

45 – 49

3.6

No formal education

6.1

Primary or Koranic school

23.5

Secondary school (WAEC/GCE)

46.2

Higher

24.2

Marital Status
Never married

5.0

Married or in-union

92.3

Widowed/divorced/separated

2.7

Number of living children

Three

21.2

Four

19.4

Five or more

19.3

How many additional children do you want to have?
Zero

33.2

One

14.4

Two

16.6

Three

12.8

Four or more

18.5

When would you like to have your next child?
In the next year

11.9

In the next two years

21.0

More than two years from now

28.0

Does not want any more children

32.6

Doesn’t know

5.2

Had previously visited the same PPMV for injectable
services

At each follow-up survey, clients who continued using
an injectable contraceptive were asked whether they had
experienced side effects in the three months preceding
Clients who began a new episode of use is defined as a client who
was not using a contraceptive method the day before their first visit
to a trained PPMV.

20 – 24

Education

Clients were asked why they chose PPMVs for injectable contraceptive services rather than going elsewhere
(Figure 24). While clients listed multiple reasons, convenient location was the most commonly cited reason
(61%). The next most commonly named reasons
included anonymous care (32%), knowing the PPMV
personally (32%), and no waiting time (31%).

10

1.2

Yes

39.8

No

61.2

Currently employed

†

Yes

60.4

No

39.6

Total

100

Percentages may not add to 100% due to missing data
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the survey. At the time of their second injection, one in five clients (20%) experienced side
effects in the preceding three months (n=382).
By the third injection, only 12 percent of clients had experienced side effects (n=327, data
not shown).

F IGURE 23. O UTC O ME O F C L IENT’ S F IRS T VISIT T O A
TRA INED P PMV FO R INJ EC TA B L E S ERVIC ES (N=5 61)

41.5%

18.5%

began a new
episode of use

switched methods

Clients who had experienced side effects were
asked whether they reported those side effects
to a PPMV or to another provider (Figure
25). At each time point, over 70 percent of
clients said that they reported the side effect
to the PPMV. The percentage who reported a
39.9%
continued with the
side effect to a health care provider increased
same method
from six percent to 16 percent between the
second and third injection. Twenty-eight percent of clients at their second interview and 24 percent at their third interview did not report their side effects
to a PPMV or other health care provider.
F IGUR E 24. C LI E NT S ’ RE A S O N S FO R C H O O S IN G PPMVS FO R INJ EC TA B L E C O NTRAC EPTIVE SERVIC ES AT FIRS T
INJECT ION BY A T R A IN E D PP MV ( N = 5 61 ) †
100%

75%

61.3
50%

31.9

31.9

31.0

29.9

29.2

28.9

Anonymous
care

Client knows
the PPMV

No waiting
time

Client gets other
services from
PPMV

Convenient
hours

Lower cost

25%

0%

†

Convenient
location

Multiple responses possible

FIGU R E 25 . RE PO RTIN G O F SID E E F F E CT S TO P PMVs O R OTH ER
PROVID E R S , AMO N G C O N TIN U IN G IN J E C TA B L E C L IENT S W H O
E XPE R IE NC ED SID E E F F E C T S IN TH E PR EC ED ING TH REE MO NTH S
100%

75%

73.7

70.5

Reported side effects to PPMV
Reported side effects to other provider

50%

Did not report side effects to provider
28.2

25%

15.8

23.7

6.4
0%

Second injection
(n=78)
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Third injection
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26.0

PPMVs always
have the drug in
stock

Clients reported receiving quality family planning counseling and were
satisfied with injectable contraceptive services received from PPMVs
To examine the quality of care received from PPMVs, clients were asked whether they received specific counseling information at each injection. Quality of care results are presented in Figure 26. Over 90 percent of
clients reported receiving information on 8 of 9 counseling items at the first injection visit. Fewer clients (82%)
were told about what actions to take to resolve a side effect.
Figure 27 presents quality of care received by clients at their second and third injections. High quality of care
continued among clients who returned to PPMVs for their second and third injections. Reported information
received was high for all items at both the second and third injection. Over 90 percent of clients were told when
to return for follow-up, felt their information would be kept confidential, felt comfortable asking questions,
were told what to do if they have problems with the injectable, and were told about the potential side effects
of the injectable.

FIGU R E 2 6 . Q UA L IT Y O F CARE RE C E IV ED AT F IRS T INJ EC TIO N BY TRA INED PPMVs (N=561)
0%

25%

50%

100%

75%

Asked reason for visit

94.5

Told you about other methods

93.8

Asked whether you had used injectables in the past

93.4

Asked your reason for choosing the injectable

92.2

Told you when to return for follow-up

98.1

Told you what to do if you have problems with the injectable

90.9

Told you about potential side effects of injectables

90.7

Suggested actions to resolve the problem with the side effect

81.8

Client felt comfortable asking questions

96.6

FIGU R E 27. QUA L IT Y O F CARE RE C E IV ED BY C O NTINUING C L IENT S AT FO L LOW - UP INJ EC TIO NS BY
T R A INE D P PMV s
0%

25%

50%

100%

75%

99.0
98.8

Told you when to return for follow-up

97.6
97.6

Told you what to do if you have problems with the injectable

90.1
92.4

Told you about potential side effects of injectables

87.7
81.7

Suggested actions to resolved the problem with the side effect

Second injection (n=382)

Third injection (n=327)
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Comparing responses from Figure 26 and 27, clients reported high quality of care from the first visit, which
continued to subsequent visits. Though fewer clients were given suggestions to resolve problems due to side
effects, nearly 90 percent of respondents received this information at their second injection.
Figure 28 presents additional
aspects of clients’ experiences
receiving injectable services
from PPMVs. Across all survey
times, nearly all respondents
reported they would recommend
the PPMV to a friend and that
they themselves would return
for injectable services. Clients in
the additional four states were
asked whether they found injectable contraceptive services from
PPMVs affordable. Seventy-two
percent of PPMVs in the additional four states felt their injectable services were affordable at
their first injection. This increased
to nearly 90 percent at the second
injection (data not shown).

F IG URE 28. OTH ER A SPEC T S O F C O NTINUING C L IENT S’ VIS IT S
TO TRA INED P PMVS FO R INJ EC TA B L E C O NTRAC EPTIVE SERVICES
100%

99.5

99.7

99.3

99.1

98.9

97.5

75%

50%

25%

0%

Will recommend this
PPMV to a friend for
injectable services

Will return to this
PPMV for injectable
services

First injection (n=561)

Felt PPMV was
knowledgeable
about injectables

Third injection (n=327)

Clients who discontinued the injectable contraceptive did so for reasons
unrelated to PPMV service quality
Based on lessons learned in Nasarawa and Oyo, clients in Bauchi, Cross River, Ebonyi and Kaduna who
discontinued the injectable or had not received their most recent injection were asked why they had not gone
back or stopped using the method (Table 8). At the time of their second injection, 18 percent of respondents
were lost to follow-up (n=52), 57 percent continued using their same injectable method (n=169), 24 percent
had discontinued the method or not received their most recent injection on time (n=71), and one percent
(n=2) had switched to another method (pill and female condoms). Among the 26 percent (n=73) who had
discontinued, had not received their most injection or switched methods, the top three reasons why clients
stopped using the injectable before receiving their second injection were: not having time to go back for their
injection (26%); side effects (19%); and their partner (12%).
At the time of the third injection, 27 percent were lost to follow-up (n=78), 51 percent had continued their
injectable method (n=150), 20 percent had discontinued their injectable method (n=60), and 2 percent (n=6)
had switched to another method (pill, implant, or condom). Among those who stopped using the injectable or
PPMV injectable services before their scheduled third injection (n=66), the top three reasons were: didn’t have
time to go back (21%); wanted to become pregnant (20%), and side effects (18%).

32

OCTOBER 2018

TA B L E 8 . R EAS O N S FO R S TO PPIN G IN J EC TA B L E METH O D AT S EC O ND A ND TH IRD
IN T E RVIE W †
Second Interview
(n=73)

Third Interview
(n=66)

Didn’t have time to go back for most recent injection

26.0

21.2

Side effects

19.2

18.2

Wanted to become pregnant

12.3

19.7

Stopped method because of partner

12.3

13.6

Partner or client was traveling

9.6

1.5

Client was pregnant

5.5

9.1

Lack of money

6.8

0.0

Forgot to go back

5.5

0.0

Didn’t like the method/wanted to stop

0.0

10.6

Other

2.7

6.1

Only asked of clients in Bauchi, Cross River, Ebonyi and Kaduna

†
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Discussion
The results of this study show that many PPMVs were providing injectable contraceptives to clients who were
voluntarily seeking these services from them, which is consistent with findings from previous studies (Ajuwon
et al., 2013; NPC and ICF, 2014). Results also show that it is feasible for PPMVs to administer injectable contraceptive services with training, mentorship and support. The study also demonstrated that the majority of
clients were satisfied with the services they received from PPMVs.

PPMVs can safely provide injectable contraceptives
After receiving a training, almost all PPMVs demonstrated the key steps for administering injectable contraceptives and this skill was retained over time. At the 6-month monitoring visit, for example, most PPMVs demonstrated all the key steps for safe DMPA-IM and DMPA-SC administration in front of a certified FP Master
Trainer. Fewer PPMVs (56%) demonstrated aspirate needle when observed at the 6-month monitoring visit.
When asked to name the DMPA-IM administration steps in the 9-month follow-up survey, however, 85 percent
named this step (data not shown). One reason why aspirate needle was low during the observations could have
been because it is difficult to demonstrate this without a real client. Results from the survey, however, suggest
that many PPMVs knew this was a key DMPA-IM administration step. Still, this DMPA-IM step should be
emphasized in future trainings to ensure PPMVs understand its importance and do it routinely.
Almost all PPMVs in Bauchi, Cross River, Ebonyi and Kaduna (observation data were not collected in Oyo
and Nasarawa) were observed having the sharps disposal box in their shops, suggesting that PPMVs will dispose of sharp waste safely when provided with disposal boxes. Even though PPMVs in this study were linked
to local government headquarters with incineration facilities for proper disposal, the study did not assess how
consistently PPMVs were taking the sharps boxes to the incineration sites. Future programmatic and research
activities may look to explore barriers to PPMVs consistent disposal of sharps at incineration locations.

There was no difference in knowledge and skills between PPMVs with and
without previous health facility experience
Some argue that PPMVs who previously worked in a health facility would be better equipped to provide
injectable contraceptive services to clients. After the training, however, PPMVs without previous health facility
experience demonstrated the same knowledge (and higher knowledge for two indicators) for 44 of the 50 indicators at the post-test survey and for 46 of the 50 indicators at the 9-month follow-up survey. Furthermore,
PPMVs without health facility experience demonstrated all the same steps required for safe administration of
DMPA-IM and DMPA-SC at the post-test and 6-month monitoring visit. These results strongly suggest that
PPMVs without previous health facility experience perform as well as PPMVs with health facility experience
when provided with proper training. Considering that only 28 percent of PPMVs in our study had previously
worked in a health facility, permitting all PPMVs to provide injectable contraceptives (given they can read and
write) could greatly improve access to FP and injectable services to communities across Nigeria.

PPMVs’ knowledge of injectable contraceptive characteristics was high after
the training and was retained nine months after the training
Although most PPMVs were already providing some type of injectable contraceptive service, PPMVs’ knowledge of injectable contraceptive methods was low before the training. Across all six states, PPMVs’ knowledge
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of injectable contraceptive characteristics increased immediately after the training and was retained nine months
later. This suggests that PPMVs can learn from a standardized training that offers information about injectable characteristics and skills to administer injectable services. PPMVs’ learned and retained some knowledge
better than others. For example, less than a quarter identified either delayed return to fertility (23%), temporary
skin irritation (21%) or decrease in sex drive (18%) as common injectable side effects at the post-test survey.
Similarly, few PPMVs named breastfeeding (21%), rheumatic disease (19%), migraines with aura (19%), or deep
vein thrombosis (13%) as exclusionary health conditions at the post-test survey. These questions were based on
spontaneous responses, so recall of certain side effects and exclusionary health conditions may be better than
others. In this study, PPMVs were given several job aids: the MEC wheel, BCS+, and the FHI 360 screening
checklist. In Bauchi, Cross River, Ebonyi and Kaduna (data not collected from PPMVs in Nasarawa and Oyo)
86 percent of PPMVs reported that they used one or more of these job aids with their clients. This suggests
that the data collection methodology used in this study may not have accurately capture PPMVs knowledge and
behaviors vis-à -vis what they tell clients. Most clients reported being told about side effects, which may reflect
the PPMVs’ use of the job aids. This also suggests that it is important to consider how these areas of knowledge can be improved: is it linked to number of clients seen or should it be emphasized in future trainings?
These areas need to be better explored in future implementation activities.

Clients reported receiving quality family planning counseling and were
satisfied with injectable contraceptive services received from PPMVs
Of the 561 clients interviewed, 42 percent were not using a method on the day before receiving their first injection from a trained PPMV (although some may have had previous episodes of using contraception). This suggests that PPMVs have the potential to broaden contraceptive availability to new contraceptive users. Results
from the client surveys complement findings from the PPMV surveys and demonstrations that suggest PPMVs
can learn and apply FP counseling and injectable contraceptive knowledge with proper support. Over 80 percent of clients reported receiving information on 11 quality of care indicators and were satisfied with injectable
services received. The clients also felt that PPMVs were knowledgeable about injectable contraceptives and
PPMVs gave them an opportunity to ask questions. Consequently, almost all clients were willing to return to the
same PPMV for future injectable services and would refer others to the PPMV for injectable services.

Clients who discontinued the injectable contraceptive did so for reasons
unrelated to PPMV service quality
Among clients who stopped using the injectable, most did so because of their desire to become pregnant. Of
the few women who experienced side effects, almost all discussed the side effects they experienced with their
PPMV. These findings suggest that women are willing to return to a PPMV to discuss issues that they may face
with the injectable contraceptive method.

Strengths & limitations of the study
There were several limitations of this study. First, it would have been useful to implement surveys to healthcare
providers in the public sector to see how PPMVs knowledge compared to staff who are currently offering these
services. Second, there were some challenges in reaching clients over time in Nasarawa and Oyo. Some clients
had moved outside of the study sites or did not have steady access to a telephone/cell phone. In Bauchi, Cross
River, Ebonyi, and Kaduna states, owning a phone or confirming regular access to a phone was added to the
client eligibility criteria, however similar difficulties were encountered.
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Third, while there exists some demand for injectable contraceptive services by PPMVs, the average number of
clients received per month was too low to include observations of client-provider interactions. Demand may
also impact PPMVs knowledge and skills. Future interventions should include a demand generation component.
Fourth, PPMVs record keeping was low. Fifty percent of PPMVs observed in Bauchi, Cross River, Ebonyi and
Kaduna had completed the record form provided by the study team at the 6-month monitoring visit. Record
keeping is important because accurate data collection would contribute to Nigeria’s ability to track contraceptive use. During the monitoring visits, many PPMVs cited police harassment for why they did not keep up-todate records. Future interventions should work with regulatory and law enforcement bodies to ensure they are
aware of PPMVs’ role in the delivery of injectable contraceptive services. Additional research is also needed on
how to effectively motivate PPMVs to keep records.
There are many strengths to this study:
1. It was a systematic study that demonstrated PPMVs across all six geopolitical zones can provide both
intramuscular and sub-cutaneous forms of the injectable contraceptive
2. Stakeholders were an integral part of the study’s implementation which underpins research utilization.
For example, the Bauchi commissioner of health has expressed her dedication in scaling-up PPMV provision of injectable services in her state.

Study implications and recommendations
Under the proper legal and regulatory framework, PPMVs have the potential to improve access to FP services. Results from Bauchi, Cross River, Ebonyi, Kaduna, Nasarawa and Oyo suggest that PPMVs can provide
injectable contraceptives safely with proper training and support. Results from the PPMV and client data confirm that there is a demand for injectable contraceptive services from PPMVs. More importantly, clients who
received services from PPMVs reported high quality of care and were satisfied with the services received.
After the training, PPMVs, regardless of their previous experience working in the formal health sector, demonstrated (a) the steps for safe administration, (b) that they could adhere to needle safety best practices, and (c)
that they could gain the key knowledge to provide injectable services. While knowledge was lower for some
indicators, specifically some of the side effects and exclusionary health conditions, most PPMVs reported using
job aids to counsel and screen clients.
With input from various stakeholders, the training curriculum was revised based on learnings from Nasarawa
and Oyo and is now ready to be used in all states for scale-up if PPMVs are authorized to provide injectable
contraceptive services. Based on these findings, the Evidence Project makes the following recommendations if
policy change allows for PPMV provision of injectable contraceptive services:
• All PPMVs should be trained using existing and validated materials. Most PPMVs in the additional four states strongly agreed that the curriculum used in this study improved their knowledge and
skills to provide FP counseling and injectable contraceptive services.
• PPMVs should be provided job aids to for FP counseling and to counsel and screen injectable
contraceptive clients.
• Linkages between the PPMVs and the public sector are needed to ensure proper referrals for
any contraceptive method and disposal of sharps.
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• PPMVs require monitoring support by the state and local governments. Additional support
would be needed to ensure PPMVs do not experience harassment from law officials. This potential
for harassment can prohibit PPMVs from keeping up-to-date records of FP counseling, and sale and
administration of injectable contraceptive services.
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